Abbott
This sponsor has funded 4 studies across 11 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 29817 | Finalised | DRIVE - Brand-specific influenza vaccine effectiveness in Europe, season 2018/19 (DRIVE 2018/19) | Yes | Yes |
| 35685 | Finalised | DRIVE - Brand-specific influenza vaccine effectiveness in Europe, season 2019/20 (DRIVE 2019/20) | Yes | Yes |
| 40875 | Finalised | DRIVE Brand-specific influenza vaccine effectiveness in Europe, season 2020/21 (DRIVE 2020/21) | Yes | Yes |
| 46888 | Finalised | DRIVE - Brand-specific influenza vaccine effectiveness in Europe, season 2021/22 (DRIVE 2021/22) | Yes | Yes |
PAS by Risk Management Plan (RMP) requirement
Abbott
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Abbott
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Abbott
11 Study countries specified are the following:
- Austria
- Finland
- France
- Greece
- Iceland
- Italy
- Luxembourg
- Romania
- Spain
- United Kingdom
- United Kingdom (Northern Ireland)